Daewoong Pharma (069620) — Cash Flow Quality Index
Daewoong Pharma (069620) has a Cash Flow Quality Index of 1.34x as of September 2025. Operating cash flow of ₩57.53 Billion exceeds net income of ₩43.09 Billion, indicating high earnings quality where cash backs reported profits. Explore 069620 cash generation efficiency to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Daewoong Pharma Cash Flow Quality Index (2007–2024)
Historical Cash Flow Quality Index for Daewoong Pharma across 15 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check total reinvestment intensity of Daewoong Pharma to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Daewoong Pharma (2007–2024)
Year-by-year earnings quality comparison for Daewoong Pharma. For live market cap and the full company financial profile, see 069620 stock market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 2.38x | ₩51.49 Billion | ₩21.61 Billion | ▲ +114.7% |
| 2023 | 1.11x | ₩132.57 Billion | ₩119.45 Billion | ▼ -28.5% |
| 2022 | 1.55x | ₩118.21 Billion | ₩76.14 Billion | ▲ +57.2% |
| 2021 | 0.99x | ₩39.99 Billion | ₩40.48 Billion | ▼ -96.9% |
| 2020 | 32.17x | ₩100.98 Billion | ₩3.14 Billion | ▲ +1129.1% |
| 2019 | 2.62x | ₩57.60 Billion | ₩22.01 Billion | ▼ -20.5% |
| 2017 | 3.29x | ₩103.94 Billion | ₩31.58 Billion | ▲ +477.2% |
| 2016 | 0.57x | ₩15.38 Billion | ₩26.97 Billion | ▼ -31.8% |
| 2015 | 0.84x | ₩35.89 Billion | ₩42.93 Billion | ▲ +1.6% |
| 2014 | 0.82x | ₩25.95 Billion | ₩31.54 Billion | ▼ -11.3% |
| 2013 | 0.93x | ₩54.16 Billion | ₩58.40 Billion | ▼ -29.8% |
| 2012 | 1.32x | ₩45.02 Billion | ₩34.08 Billion | ▼ -15.9% |
| 2011 | 1.57x | ₩78.82 Billion | ₩50.19 Billion | ▲ +65.1% |
| 2008 | 0.95x | ₩31.33 Billion | ₩32.93 Billion | ▲ +117.3% |
| 2007 | 0.44x | ₩25.81 Billion | ₩58.95 Billion | — |